Curadev Pharma

Curadev, Roche ink research cancer immunotherapeutic collaboration

Wednesday, April 22, 2015

Curadev Pharma, headquartered in New Delhi, India, has entered into a research collaboration and exclusive license agreement with Roche for the development and commercialization of IDO1 and TDO inhibitors. The agreement covers the development of the lead preclinical immune tolerance inhibitor and a research collaboration with Roche’s research and early development organization to further explore the IDO and TDO pathways.

[Read More]